Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
Ivana Gojo(Johns Hopkins University), Rajat Bannerji(Rutgers, The State University of New Jersey), Eric J. Feldman(The University of Texas MD Anderson Cancer Center), Mariola Sadowska(University of Maryland, Baltimore), Karen Small(Merck & Co., Inc., Rahway, NJ, USA (United States)), Maria R. Baer(University of Maryland, Baltimore), Jennifer Poon(Novartis (Switzerland)), Yali Zhu(Guangzhou Women and Children Medical Center), Rena G. Lapidus(University of Maryland, Baltimore), Ying-Ming Jou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alison Walker(East Midlands Ambulance Service NHS Trust), Da Zhang(Fujian Medical University), Edward A. Sausville(University of Maryland, Baltimore), Swaminathan P. Iyer(The University of Texas MD Anderson Cancer Center)
Cited by 94
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764